BE Study of Bilayer Combination of Gemigliptin/Rosuvastatin 50/20mg in Comparison to Monolayer Combination.
Status:
Unknown status
Trial end date:
2019-08-31
Target enrollment:
Participant gender:
Summary
To evaluate and compare PK/PD, safety and tolerability of monolayer combination of
Gemigliptin/Rosuvastatin 50/20mg and bilayer combination of Gemigliprin/Rosuvastatin 50/20mg
in healthy adults.